Ignite Creation Date:
2024-05-06 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05724290
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2023-02-13
First Post:
2023-02-07
Brief Title:
Mechanism of EGR2 in Allergic Rhinitis
Sponsor:
Zu-xia Ma
Organization:
Zunyi Medical College
Study Overview
Official Title:
The Regulatory Mechanism of EGR2 Mediated by miR-150-5p on Allergic Rhinitis
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
EGR2 may be a target for the treatment of nasal polyps
Detailed Description:
There is much debate about the etiology of nasal polyps so the pathogenesis of nasal polyps still needs to be clarified Surgery for noninflammatory nasal polyps may be better control but surgery is not effective for recurrent sinusitis and nasal polyps Therefore more research is needed to determine the best targeted therapy for nasal polyps We found that EGR2 expression was upregulated in CRSwNP patients with allergic rhinitisIn addition the expression of EGR2 in CRSwNP mucosa was significantly higher than that in the control group and the expression of EGR2 in CRSwNP with allergic rhinitis was higher than that in CRSwNP without allergic rhinitis EGR2 may be involved in the pathogenesis of nasal polyps and may also be related to the severity and recurrence of nasal polyps EGR2 may be a target for the treatment of nasal polyps
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None